Recruitment gets a prospective participant into a clinical trial; retention keeps them in it through the visits and procedures the protocol requires. The two are related but administratively distinct, and treating retention as an afterthought to recruitment — a marketing problem to be solved with reminder calls and gift cards — misses that retention activity sits inside the same human-subjects-protection framework as recruitment itself. Communication with enrolled participants, payment schedules, and how a site handles a participant who stops responding are all subject to IRB oversight and Common Rule/FDA consent requirements, not just study-coordinator judgment.
This guide covers retention as an operational and compliance topic: what counts as retention versus recruitment or enrollment, why attrition matters beyond simply losing a data point, the IRB’s role in reviewing retention communications and payment structures, how withdrawal rights interact with retention efforts, how sites track participants who stop responding, and how differential attrition can undermine the demographic diversity a trial achieved at enrollment. For the recruitment side — channels, IRB review of advertising materials, and screening into enrollment — see Clinical Trial Patient Recruitment: Methods, Screening, and Enrollment.
What Counts as Patient Retention in a Clinical Trial
Retention refers to a participant remaining enrolled and continuing to complete the protocol-required visits and procedures through their planned duration of participation. That duration is study-specific — it may be a single follow-up visit, a multi-year longitudinal schedule, or continuation through a defined primary-endpoint visit — so “retention” is always relative to what the protocol asked of that participant, not a fixed calendar length.
Sites and sponsors typically track a retention rate: the proportion of enrolled participants who complete their expected participation, often measured at defined milestones (a 6-month visit, the primary endpoint assessment, end of study) rather than only at the very end. A participant who does not complete can fall into several distinct categories, and the distinction matters for both reporting and analysis:
- Withdrawal of consent. The participant affirmatively tells the site they no longer wish to continue. This is a protected right under informed consent regulations (see below) and must be documented and reported per the protocol and IRB requirements.
- Lost to follow-up (LTFU). The site can no longer reach the participant through the contact methods on file, but the participant has not formally withdrawn. LTFU is a tracking and outreach problem, not a consent event, though a site must still document its attempts to re-establish contact.
- Investigator-initiated discontinuation. The investigator withdraws the participant — for a safety event, a protocol deviation, loss of eligibility, or at the sponsor’s direction — independent of the participant’s own wishes.
These categories feed directly into the statistical analysis population (intent-to-treat versus per-protocol) and into what a site is required to report to the IRB and sponsor, so a clean, consistently-applied definition of each in the site’s SOPs is itself a retention-adjacent administrative task.
Why Retention Is an Operational and Compliance Issue, Not Just an Outreach Problem
A protocol’s sample size is powered around a target number of participants completing the study, not merely enrolling in it. Attrition above the rate assumed in the statistical analysis plan erodes that power, which can force a sponsor to extend recruitment, reopen sites, or in the worst case leave a trial unable to answer its primary question — all real cost and timeline consequences that trace back to a retention shortfall rather than a recruitment one.
Retention also has a data-quality dimension distinct from simple sample-size loss: if participants who drop out differ systematically from those who complete — for example, if attrition is higher among participants experiencing a particular side effect, or concentrated in a specific demographic subgroup — the resulting missing data is not random. Informative or differential dropout of this kind can bias a trial’s results even when the overall sample size still looks adequate on paper, which is why sponsors and monitors track not just how many participants are lost but the pattern of who is being lost and why (see the diversity section below for how this connects to enrollment-diversity goals specifically).
Retention Strategies and the IRB’s Role
The same principle that requires IRB review of recruitment advertising applies to retention communications: any written or verbal material used to encourage a currently-enrolled participant to continue — appointment-reminder letters, calls, texts, study newsletters, or messages describing the trial’s progress — is information provided to a subject and falls within the IRB’s authority to review materials that could influence a participant’s decisions about their continued involvement. A site that treats retention outreach as routine administrative correspondence exempt from that review is applying a narrower reading of IRB oversight than the recruitment side of the same trial typically receives. See the recruitment guide’s discussion of the advertising-approval requirement for the parallel rule on the recruitment side.
Retention strategies that don’t touch consent or payment at all are usually the least regulatorily sensitive and the most effective in practice: flexible visit windows, decentralized or remote visit options (telehealth check-ins, local labs, home-health visits where the protocol allows them), consolidating visits or procedures where scientifically defensible to reduce participant burden, and straightforward logistics support such as transportation or parking reimbursement.
Retention Payments and Undue Inducement
Where a site offers or increases payment to encourage continued participation, FDA and OHRP guidance set the operative framework. FDA’s Payment and Reimbursement to Research Subjects: Guidance for Institutional Review Boards and Clinical Investigators (issued January 2018) treats payment as a recruitment and retention incentive, not a benefit weighed in the IRB’s risk-benefit analysis; reimbursement for travel or lodging alone does not, by itself, raise undue-influence concerns; the full payment for a study should not be made entirely contingent on completing the whole study, though a modest completion bonus layered on top of payments already accrued for completed visits is generally acceptable as long as it is not itself coercive; and the amount and schedule of any payment must be disclosed in the informed consent document. OHRP and SACHRP’s Attachment A guidance on payment to research subjects (2019) reinforces that there is no fixed dollar threshold in federal regulation for when a payment becomes an undue inducement — it is a case-by-case IRB judgment weighing the payment’s size and structure against the study’s risk and the vulnerability of the population, consistent with the informed-consent and IRB-review requirements at 45 CFR 46.116(a)(1)/46.111(b) and 21 CFR 50.20. A retention-payment structure a site is considering — a bonus for finishing the last visit, a raffle, an escalating per-visit rate — should go through the same IRB review as the original payment schedule, not be adopted informally mid-study.
Withdrawal Rights and the Informed Consent Process
Common Rule and FDA informed-consent requirements (45 CFR 46.116; the parallel FDA consent-elements requirement at 21 CFR 50.25 for FDA-regulated research) require that participants be told they may discontinue participation at any time without penalty or loss of benefits to which they are otherwise entitled. That right sets a hard boundary on retention strategy: a site can encourage continued participation through the legitimate means described above, but it cannot make withdrawal costly, difficult, or contingent on forfeiting something the participant was already entitled to.
Two retention-adjacent process points follow from this. First, a protocol amendment that changes the visit schedule, adds procedures, or meaningfully changes the risk profile mid-study can require re-consenting currently enrolled participants — a retention-relevant administrative task in its own right, since the site needs a plan for reaching and re-consenting an active cohort without creating the kind of disruption that itself drives attrition. Second, sites should distinguish a documented withdrawal of consent from a participant simply missing a scheduled visit; the latter is an LTFU tracking question, addressed below, not a consent event, and the two carry different documentation and reporting obligations. A site’s monitoring plan — see Clinical Trial Monitoring: Visit Types, Source Data Verification & the Monitoring Plan — is typically where this distinction gets operationalized and checked.
Tracking Lost-to-Follow-Up and Long-Term Follow-Up
LTFU tracking is a defined workflow, not a passive wait-and-see process: sites document contact attempts (calls, letters, alternate contacts on file) against a pre-specified schedule, and escalate if those attempts fail. For studies with a long-term follow-up requirement that extends well beyond active treatment — oncology survival endpoints, device registries, and similar designs — sites and sponsors sometimes use third-party person-locating services to re-establish contact with participants who have become unreachable through routine site channels. That practice carries its own privacy and consent considerations: whether and how the use of a locating service was described to the participant at consent, and what information may be disclosed to the vendor, are questions the IRB should have reviewed rather than something added informally once a participant goes quiet. See Third-Party Person-Locating Services for Long-Term Follow-Up (LTFU) Data Collection for how that specific mechanism works.
Diversity, Attrition, and the Diversity Action Plan Connection
Under FDORA, sponsors of certain pivotal drug and device trials must submit an FDA Diversity Action Plan setting enrollment goals by age, sex, race, and ethnicity — see FDA Diversity Action Plans for Clinical Trials: Requirements and Status for what the requirement covers, which studies are in scope, and the current status of FDA’s implementing guidance. That requirement is framed around enrollment, but enrollment diversity achieved at the start of a trial is not self-sustaining through to the primary analysis: if completion rates differ meaningfully across the same demographic subgroups a Diversity Action Plan sets goals for, the trial can lose at analysis the representativeness it achieved at enrollment — and, per the missing-data point above, that kind of differential attrition can also bias results if dropout correlates with both subgroup and outcome.
The administrative implication is that retention and completion should be tracked and reported broken out by the same demographic categories used for enrollment goals, not just aggregated. Where a subgroup shows disproportionate dropout, the same kind of qualitative barrier review commonly recommended for enrollment — transportation, childcare, language access, health-literacy of materials, and, in populations with a history of research-related harm, legitimate distrust of the research process — is the relevant lens for retention as well, rather than treating diversity as a box checked once enrollment targets are hit.
How Retention Planning Connects to Recruitment and Site Operations
Retention planning doesn’t sit in isolation from the rest of trial operations. A site’s historical retention performance is itself a relevant input during site selection and feasibility assessment — a site that recruits well but retains poorly changes the net accrual math a sponsor is planning around. Some vendors in the clinical trial recruitment vendor landscape also offer retention-specific services (patient engagement platforms, reminder/scheduling technology, concierge logistics support) alongside recruitment outreach, so a sponsor evaluating a vendor for one function may reasonably ask what it offers for the other. And because recruitment materials and retention communications are reviewed under the same IRB authority, a site’s regulatory-document workflow benefits from treating the two as one continuous submission and tracking process rather than two separate ones.
Frequently Asked Questions
What is a good clinical trial retention rate?
There is no single benchmark retention rate that applies across trials — acceptable and typical rates vary substantially by therapeutic area, participation burden, and study duration, and a rate that would be a red flag for a short single-visit study may be unremarkable for a multi-year longitudinal design. Sponsors set retention assumptions in the statistical analysis plan for each specific protocol rather than against an industry-wide figure.
What’s the difference between retention and recruitment in a clinical trial?
Recruitment is the process of identifying, approaching, and enrolling participants; retention is keeping already-enrolled participants engaged through their planned course of participation. A trial can have strong recruitment and weak retention, or the reverse — they are tracked and managed as distinct metrics with different failure points.
Do retention communications need IRB approval?
Generally yes. Reminder letters, calls, texts, and other materials directed at currently-enrolled participants to encourage continued participation are information provided to subjects and fall within the IRB’s authority to review materials that could influence a participant’s decisions, the same principle that requires IRB review of recruitment advertising.
Is it ethical to offer participants extra payment to finish a study?
A modest completion bonus layered on top of payments already earned for completed visits is generally acceptable under FDA and OHRP guidance as long as it is not itself coercive and the amount/schedule is disclosed in the consent document; making the entire payment contingent on finishing the whole study is the pattern regulators specifically flag as raising undue-inducement concerns. There is no fixed dollar threshold — it is a case-by-case IRB determination.
How does participant attrition affect an FDA Diversity Action Plan?
A Diversity Action Plan sets enrollment goals, but if completion rates differ across the demographic subgroups those goals target, a trial can lose at final analysis the representativeness it achieved at enrollment. Tracking retention broken out by the same subgroups — not just enrollment — is how sites and sponsors catch that erosion early enough to address it.
